Panbela Therapeutics EBIT

Panbela Therapeutics (PBLA) currently reports a EBIT of $-44M as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. That is below the Technology sector average of $12T. Use the charts on this page to explore Panbela Therapeutics's EBIT history and peer comparisons.

Panbela Therapeutics's EBIT decreased from $-32M to $-44M — a 40.4% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Panbela Therapeutics's EBIT of $-44M is lower than the Technology sector average of $12T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Panbela Therapeutics reported $-44M in EBIT as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-44M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is $12T. From there, open related valuation or income-statement pages for Panbela Therapeutics, and consider following PBLA for alerts when major investors trade the stock.